Treg Cell Immunotherapy in Cancer
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 28 February 2025 | Viewed by 475
Special Issue Editor
Special Issue Information
Dear Colleagues,
T regulatory (Treg) cells comprise a distinct subset of the CD4+ T cells with immune suppressive properties which are central regulators of peripheral tolerance. Their critical roles in maintaining immune homeostasis are well established, as both mice and humans with Treg cell defects develop catastrophic multiorgan autoimmunity. Because of their pivotal immunoregulatory properties, though, Treg cells can have detrimental effects when present in sites where immune responses are desired, as is the tumor microenvironment.
The presence of Treg cells in various types of cancer is known to severely dampen antitumor immune responses, both endogenous and treatment induced, and is considered a roadblock for all current types of cancer immunotherapies. Depleting Treg cells from the tumor microenvironment has the potential to immensely improve antitumor immune responses, but Treg targeting approaches are being challenged by 2 main issues: (i) Treg cells share many markers with conventional T cells and therefore cannot be utilized as targets to specifically eradicate Treg cells without interfering with effector functions, (ii) universal Treg cell depletion can be complicated with severe autoimmunity.
This issue of Cancers is dedicated to this topic, aiming to contribute to better understanding of the aspects of Treg biology which shape antitumor immune responses and the potential of developing successful Treg targeting therapeutic interventions to improve cancer immunotherapy. We aim to cover all associated areas, including but not limited to the mechanisms of Treg cell migration, adaptation and survival in the tumor microenvironment, mechanisms of Treg mediated suppression of antitumor immune responses, and mainly novel therapeutic approaches to target Treg cells specifically in the tumor without causing autoimmune phenomena or interfering with effector functions. Reviews on the above topics are also welcome.
We are looking forward to receiving your work.
Dr. Maria Velegraki
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- treg cells
- cancer immunotherapy
- immune evasion
- antitumor immune responses
- targeting therapeutic interventions
